ascophyllum and Hyperlipidemias

ascophyllum has been researched along with Hyperlipidemias* in 3 studies

Other Studies

3 other study(ies) available for ascophyllum and Hyperlipidemias

ArticleYear
    Nutrients, 2022, Nov-04, Volume: 14, Issue:21

    Topics: Animals; Ascophyllum; Cholesterol; Diet; Fucus; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Lipase; Lipid Metabolism; Male; Metabolic Diseases; Plant Extracts; Rats

2022
Fucoidan A2 from the Brown Seaweed Ascophyllum nodosum Lowers Lipid by Improving Reverse Cholesterol Transport in C57BL/6J Mice Fed a High-Fat Diet.
    Journal of agricultural and food chemistry, 2019, May-22, Volume: 67, Issue:20

    Reverse cholesterol transport (RCT) is a physiological process, in which excess peripheral cholesterol is transported to the liver and further excreted into the bile and then feces. Recently, fucoidans are reported to have a lipid-lowering effect. This study was designed to investigate whether fucoidan from the brown seaweed Ascophyllum nodosum lowers lipid by modulating RCT in C57BL/6J mice fed a high-fat diet. Our results indicated that fucoidan intervention significantly reduced plasma triglyceride, total cholesterol, and fat pad index and markedly increased high-density lipoprotein cholesterol in a dose-dependent manner. In the liver, fucoidan significantly increased the expression of peroxisome proliferator-activated receptor (PPAR)α, PPARγ, liver X receptor (LXR)β, adenosine triphosphate (ATP) binding cassette (ABC)A1, ABCG8, low-density lipoprotein receptor (LDLR), scavenger receptor B type 1 (SR-B1), and cholesterol 7-α-hydroxylase A1 (CYP7A1) and decreased the triglyceride level and expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) and PPARβ but had no effect on LXRα, ABCG1, and ABCG5. In the small intestine, the fucoidan treatment significantly reduced the expression of Niemann-Pick C1-like 1 (NPC1L1) and improved ABCG5 and ABCG8. These results demonstrated that fucoidan can improve lipid transfer from plasma to the liver by activating SR-B1 and LDLR and inactivating PCSK9 and upregulate lipid metabolism by activating PPARα, LXRβ, ABC transporters, and CYP7A1. In the small intestine, this fucoidan can decrease cholesterol absorption and increase cholesterol excretion by activating NPC1L1 and ABCG5 and ABCG8, respectively. In conclusion, fucoidan from A. nodosum may lower lipids by modulating RCT-related protein expression and can be explored as a potential compound for prevention or treatment of hyperlipidemia-related diseases.

    Topics: Animals; Ascophyllum; ATP Binding Cassette Transporter, Subfamily G, Member 5; Biological Transport; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Diet, High-Fat; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Plant Extracts; Polysaccharides; Receptors, LDL; Receptors, Scavenger; Seaweed

2019
The fucoidan A3 from the seaweed Ascophyllum nodosum enhances RCT-related genes expression in hyperlipidemic C57BL/6J mice.
    International journal of biological macromolecules, 2019, Aug-01, Volume: 134

    Reverse cholesterol transport (RCT) has been demonstrated to reduce hyperlipidemia, and fucoidans are found to possess hypolipidemic effect. This study was designed to investigate the lipid-lowering effect of the fucoidan from the brown seaweed A. nodosum and whether it improves RCT-related genes expression in C57 BL/6J mice. Our results indicated that fucoidan A3 (100 mg/kg/day) intervention significantly reduced plasma total cholesterol (~23.2%), triglyceride (~48.7%) and fat pad index. This fucoidan significantly increased the mRNA expression of low-density lipoprotein receptor (LDLR), scavenger receptor B type 1 (SR-B1), cholesterol 7 alpha-hydroxylase A1 (CYP7A1), liver X receptor (LXR) β, ATP-binding cassette transporter (ABC) A1 and sterol regulatory element-binding protein (SREBP) 1c, and decreased the expression of peroxisome proliferator-activated receptor (PPAR) γ, however, it had no effect on the expression of proprotein convertase subtilisin/kexin type 9, PPARα, LXRα, SREBP-2, ABCG1, ABCG8 and Niemann-Pick C1-like 1. These results demonstrated that this fucoidan improved lipid transfer from plasma to the liver by activating SR-B1 and LDLR, and up-regulated lipid metabolism by activating LXRβ, ABCA1 and CYP7A1. In conclusion, this fucoidan lowers lipid by enhancing RCT-related genes expression, and it can be explored as a potential candidate for prevention or treatment of lipid disorders.

    Topics: Animals; Ascophyllum; ATP Binding Cassette Transporter 1; Biological Transport; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Disease Models, Animal; Gene Expression Regulation; Hyperlipidemias; Hypolipidemic Agents; Intestine, Small; Liver; Male; Mice; Mice, Inbred C57BL; Polysaccharides; Receptors, LDL; RNA, Messenger; Scavenger Receptors, Class B; Seaweed

2019